SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--TRex Bio, Inc., (“TRexBio”), a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, today announced the ...
Prognostic value of host genetic variants determining Bifidobacterium abundance in the lactose metabolism pathway for immunotherapy efficacy. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces ...
Data from human atopic dermatitis (“AD”) skin identify altered tissue Treg programs and support TNFR2 as a regulator of immune homeostasis in tissue TRB-061, a novel TNFR2 agonist, induced selective ...
A special group of immune cells known as regulatory T cells, or Tregs for short, became an overnight sensation when a trio of U.S. and Japanese scientists won the Nobel Prize in physiology or medicine ...
Coya Therapeutics’ pipeline candidates focus on improving the quantity and functionality of regulatory T cells to alleviate the inflammatory processes associated with the progression of ...
“Our approach is about helping the patient’s own immune system create a safer environment for the stem cell transplant,” said senior author, Robert Levy. “We’re not just suppressing the immune ...
All three conditions share common hallmark of complex inflammatory pathways underlying disease pathophysiology that involve dysfunctional regulatory T cell (Treg) biology which may limit efficacy of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results